Mean Organ Dose, Number of Deaths and Relative Risks of Mortality Due to Selected Cancers by Dose Categories

Categories	Mean Organ dose (Gy)	na	Pyrsb	RRc	95% CId	Categories	Mean organ dose (Gy)	na	Pyrsb	RRc	95% CId
Uterine cervix						Uterine corpus
No RTe	0	7	71,392	1.00		No RTe	0	8	71,392	1.00
0–44	13	11	47,155	1.98	0.77–5.42	0–12.4	7	26	41,758	4.70	2.22–11.12
45–89	78	5	30,024	1.09	0.31–3.59	12.5–25.4	17	19	19,091	6.04	2.69–14.86
90–134	119	19	68,459	2.11	0.90–5.52	25.5–37.4	31	44	61,777	4.32	2.12–10.02
135–179	151	8	20,412	2.84	0.99–8.38	37.5–49.0	40	40	43,029	6.10	2.99–14.14
≥180	205	4	21,535	1.51	0.39–5.11	≥50.0	58	18	21,930	5.53	2.47–13.57
Bladder						Rectum
No RTe	0.00	5	71,395	1.00		No RTe	0.00	4	71,395	1.00
0.0–5.9	4.28	5	3,306	1.69	0.47–6.10	0.0–2.24	1.39	1	11,538	1.59	0.08–10.86
6.0–7.9	6.89	15	43,124	4.21	1.63–13.00	2.25–4.4	3.25	9	58,183	2.22	0.71–8.30
≥8.0	10.31	12	59,784	2.35	0.86–7.49	4.5–6.74	5.70	13	47,563	3.80	1.31–13.75
						6.75–8.69	7.90	4	16,126	3.56	0.83–15.25
						≥9.0	12.99	3	12,951	3.29	0.64–15.24
Ovary						Colon
No RTe	0.00	15	71,392	1.00		No RTe	0.00	44	71,392	1.00
0.0–1.9	1.43	10	40,544	1.35	0.57–3.05	0.0-0.9	0.59	15	24,144	1.10	0.59–1.95
2.0–3.9	2.90	35	76,592	2.31	1.26–4.45	1.0–1.9	1.37	79	79,592	1.53	1.05–2.26
4.0–5.9	5.29	20	35,393	2.96	1.47–6.08	2.0–2.9	2.55	40	40,793	1.47	0.94–2.28
6.0–7.9	6.95	9	16,589	2.76	1.14–6.30	3.0–3.9	3.49	17	19,803	1.30	0.72–2.26
≥8.0	10.56	14	18,467	3.87	1.81–8.23	≥4.0	5.54	25	23,254	1.64	0.98–2.69
Liver, gallbladder and bile ducts						Stomach
No RTe	0.00	11	71,395	1.00		No RTe	0.00	16	71,392	1.00
0–0.224	0.15	15	93,709	0.93	0.42–2.13	0–0.24	0.16	17	65,037	0.86	0.42–1.74
0.225–0.44	0.31	5	32,453	0.88	0.28–2.42	0.25–0.4	0.31	18	62,422	1.02	0.52–2.03
0.45–0.674	0.54	10	31,808	1.70	0.68–4.20	0.5–0.74	0.62	7	30,196	0.70	0.27–1.67
0.675–0.89	0.77	4	11,611	1.88	0.51–5.67	0.75–0.9	0.86	3	12,834	0.71	0.16–2.16
≥0.9	1.30	1	16,545	0.35	0.02–1.81	≥1.0	1.37	8	17,097	1.47	0.59–3.38
Kidney					Pancreas
No RTe	0.00	6	71,392	1.00		No RTe	0.00	23	71,392	1.00
0–0.24	0.17	9	86,061	1.25	0.43–3.88	0–0.24	0.15	41	100,722	1.43	0.84–2.49
0.25–0.4	0.33	3	40,745	0.81	0.17–3.13	0.25–0.4	0.31	9	23,926	1.11	0.48–2.32
0.5–0.74	0.66	4	28,208	1.62	0.40–6.02	0.5–0.74	0.66	11	29,969	1.27	0.58–2.63
0.75–0.9	0.91	1	11,425	1.01	0.05–6.17	0.75–0.9	0.87	5	5,872	3.07	1.02–7.58
≥1.0	1.47	3	21,147	1.61	0.33–6.40	≥1.0	1.48	3	27,097	0.37	0.09–1.09
Breast (dose for breast)						Breast (dose for ovary)
No RTe	0.00	67	71,392	1.00		No RTe	0.00	67	71,392	1.00
0–0.024	0.02	22	25,439	1.00	0.60–1.62	0.0–1.9	1.43	34	40,544	0.95	0.61–1.46
0.025–0.04	0.04	69	85,248	0.85	0.60–1.22	2.0–3.9	2.90	62	76,592	0.84	0.59–1.21
0.05–0.074	0.06	40	47,925	0.89	0.57–1.30	4.0–5.9	5.29	27	35,393	0.81	0.50–1.27
0.075–0.09	0.08	8	13,397	0.63	0.27–1.24	6.0–7.9	6.95	16	16,589	1.00	0.56–1.71
≥0.10	0.13	14	15,577	0.94	0.50–1.65	≥8.0	10.56	14	18,467	0.80	0.43–1.39
Brain (dose for ovary)						Non-Hodgkin lymphoma
No RTe	0.00	2	71,392	1.00		No RTe	0.00	20	92,397	1.00
0–2.9	1.85	8	86,936	6.21	1.41–43.63	0.0–0.7	0.50	28	133,723	1.04	0.59–1.87
3.0–5.9	4.41	8	65,593	8.18	1.84–57.95	0.8–1.5	1.13	7	48,527	0.64	0.25–1.44
≥6.0	8.90	1	35,056	1.78	0.08–19.44	1.6–2.3	1.82	5	39,864	0.62	0.21–1.53
						≥2.4	3.33	3	25,463	0.56	0.13–1.63
Hodgkin lymphoma						Multiple myeloma
No RTe	0.00	4	92,397	1.00		No RTe	0.00	8	92,397	1.00
0.0–0.7	0.50	3	133,723	0.45	0.09–2.04	0.0–0.7	0.50	8	133,723	0.77	0.28–2.08
0.8–1.5	1.13	4	48,527	1.64	0.39–6.91	0.8–1.5	1.13	6	48,527	1.40	0.46–4.03
1.6–2.3	1.82	1	39,864	0.48	0.03–3.25	1.6–2.3	1.82	3	39,864	0.96	0.21–3.32
≥2.4	3.33	1	25,463	0.77	0.04–5.21	≥2.4	3.33	0	25,463	0.00	—f
Leukemia						Non-CLLg leukemia
No RTe	0.00	10	92,397	1.00		No RTe	0.00	3	92,397	1.00
0.0–0.7	0.50	35	133,723	2.33	1.20–4.97	0.0–0.7	0.50	25	133,723	5.66	1.99–23.75
0.8–1.5	1.13	17	48,527	2.89	1.35–6.55	0.8–1.5	1.13	12	48,527	6.97	2.21–30.56
1.6–2.3	1.82	10	39,864	2.13	0.87–5.18	1.6–2.3	1.82	6	39,864	4.32	1.14–20.44
≥2.4	3.33	5	25,463	1.67	0.52–4.69	≥2.4	3.33	5	25,463	5.62	1.38–27.37

Note. Relative risks and 95% confidence intervals for Lymphatic/Hematopoietic cancerswere calculated based on standardized mortality rate regression.

^aNumber of deaths.

^bPerson-years.

^cRelative risk.

^d95% confidence interval.

^eRadiotherapy.

^fNot applicable.

^gChronic lymphocytic leukemia.